Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the fourth quarter and fiscal year ended June 30, 2010.

27 Aug 2010

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

In its review of the BLA, the FDA stated the T-DM1 trials did not meet the standard for accelerated approval because all available treatment choices approved for metastatic breast cancer, regardless of HER2 status, had not been exhausted in the study population.

27 Aug 2010

Octapharma completes clinical development of Uniplas human pooled plasma

Octapharma AG, one of the largest private manufacturers of plasma products in the world, announced today that the clinical development for Uniplas® has been successfully completed. The product has been filed for registration in Europe and will be submitted later in the USA.

26 Aug 2010

FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL

The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orphan Products Development was granted on August 6th, 2010.

26 Aug 2010

Nabi receives US patent for treatment and prevention of nicotine addiction with NicVAX conjugate vaccines

Nabi Biopharmaceuticals announced the receipt of a patent for treating and preventing nicotine addiction with NicVAX® and related nicotine conjugate vaccines. The United States Patent and Trademark office issued U.S. Patent No. 7,776,620 entitled "Hapten-carrier conjugates for treating and preventing nicotine addiction" for the exclusive use of methods for treating and preventing nicotine addiction with NicVAX and related nicotine vaccines. This patent runs through December 2018.

26 Aug 2010

Biogen to publish data on two-step assay for anti-JC virus antibody detection

Biogen Idec and Elan Corporation, plc today announced data has been published in the Annals of Neurology on an investigational, two-step assay to detect anti-JC virus (JCV) antibodies in human serum and plasma

26 Aug 2010

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

ZymoGenetics, Inc. today announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection.

25 Aug 2010

Doctoral students receive insights on potential career paths at symposium hosted by Emergent Biosolutions

Emergent BioSolutions Inc.today hosted "Looking Beyond the Bench," a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based industry, provided insight on potential career paths awaiting biomedical researchers.

25 Aug 2010

Improvement in mumps vaccine administration needed to prevent future outbreaks

Although immunity to mumps is high in the United States, mumps vaccine coverage must be maintained and improved to prevent future outbreaks, according to a new study, now available online (http://www.journals.uchicago.edu/doi/full/10.1086/655394), in the September 1, 2010 issue of The Journal of Infectious Diseases.

25 Aug 2010

CMC Biologics completes new, disposable manufacturing facility at Seattle

CMC Biologics, a Contract Manufacturing Organization with manufacturing sites in Europe and the USA, today announced the completion of a new state-of-the-art disposable manufacturing facility at its Seattle, WA site. The addition comes as part of a staged major expansion plan, which will add significant production capacity to its existing facility to accommodate a growing demand for cGMP manufacture of biopharmaceuticals.

25 Aug 2010

Study finds measurable immunity to pandemic H1N1 virus in Norway population

By autumn 2009, almost half of the population of Norway had been vaccinated against the pandemic influenza A (H1N1) virus. Many had also been infected by the virus during the summer and autumn outbreaks. The majority of those who were vaccinated or were infected are expected to have developed immunity to the virus.

25 Aug 2010

Eisai's Phase III trial of Perampanel for epilepsy shows positive results

The double-blind, placebo-controlled, parallel-group study (Study 306) showed that perampanel was well-tolerated and effective in reducing median seizure frequency and increasing responder rates, the primary outcome measures in the United States and European Union, respectively. The findings were highly statistically significant in 4 mg and 8 mg doses compared to placebo.

25 Aug 2010

Researchers develop high-resolution technology to visualize individual virus particles

In the war against infectious disease, identifying the culprit is half the battle. Now, research professor Shaopeng Wang and his colleagues from the Biodesign Institute at Arizona State University, describe a new method for visualizing individual virus particles. Their research opens the door to a more detailed understanding of these minute pathogens, and may further the study of a broad range of micro- and nanoscale phenomena.

25 Aug 2010

EPA selects Precision Antibody to develop monoclonal antibodies for 'Crypto' intestinal parasite

Precision Antibody™ announced today its selection by the United States Environmental Protection Agency (EPA) to develop monoclonal antibodies to two species of Cryptosporidium, an intestinal parasite that has emerged over the past 20 years as one of the most common causes of waterborne illness in the United States.

24 Aug 2010

Researchers develop new instrumentation to simplify testing patients for infectious diseases

Arizona State University researchers have demonstrated a way to dramatically simplify testing patients for infectious diseases and unhealthy protein levels.New testing instrumentation developed by Antonia Garcia and John Schneider promises to make the procedure less costly and produce results in less time.

24 Aug 2010

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Alexion Pharmaceuticals, Inc. today announced that the US Food and Drug Administration (FDA) has approved Alexion's Rhode Island manufacturing facility (ARIMF) in Smithfield, Rhode Island as a second source of commercial supply for Soliris® (eculizumab).

23 Aug 2010

New antisense drugs may help treat accidental infections: Study

New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure-suggesting the approach holds promise for treating accidental infections in laboratory or hospital settings.

23 Aug 2010

Researchers find new way to study oncogene's role in DNA repair

A key step in understanding the origins of familial breast cancer has been made by two teams of scientists at the University of California, Davis. The researchers have purified, for the first time, the protein produced by the breast cancer susceptibility gene BRCA2 and used it to study the oncogene's role in DNA repair.

23 Aug 2010

Melanoma Research Alliance announces grant to support six research programs

The Melanoma Research Alliance today announced $5.2 million in grants to support six multidisciplinary teams pursuing innovative, translational research approaches designed to benefit melanoma patients.

21 Aug 2010

Immunosuppressive therapy benefits necrotizing myopathy patients with novel autoantibody specificity

Researchers at Johns Hopkins University School of Medicine have identified a subgroup of patients with necrotizing myopathy who have a novel autoantibody specificity that makes them potential candidates for immunosuppressive therapy. The complete study is published in the September issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

20 Aug 2010

Antibody News and Research

Further Reading

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

Octapharma completes clinical development of Uniplas human pooled plasma

FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL

Nabi receives US patent for treatment and prevention of nicotine addiction with NicVAX conjugate vaccines

Biogen to publish data on two-step assay for anti-JC virus antibody detection

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

Doctoral students receive insights on potential career paths at symposium hosted by Emergent Biosolutions

Improvement in mumps vaccine administration needed to prevent future outbreaks

CMC Biologics completes new, disposable manufacturing facility at Seattle

Study finds measurable immunity to pandemic H1N1 virus in Norway population

Eisai's Phase III trial of Perampanel for epilepsy shows positive results

Researchers develop high-resolution technology to visualize individual virus particles

EPA selects Precision Antibody to develop monoclonal antibodies for 'Crypto' intestinal parasite

Researchers develop new instrumentation to simplify testing patients for infectious diseases

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

New antisense drugs may help treat accidental infections: Study

Researchers find new way to study oncogene's role in DNA repair

Melanoma Research Alliance announces grant to support six research programs

Immunosuppressive therapy benefits necrotizing myopathy patients with novel autoantibody specificity

Monoclonal Antibody Manufacturing Trends eBook eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News